Athena launches Alzheimer's specific assays
This article was originally published in Clinica
Executive Summary
Athena Neurosciences has launched the first disease-specific tests for Alzheimer's. ADmark Assays will allow neurologists to approach diagnosis of the disease by a process of inclusion, rather than exclusion, says Athena. One of a pair of tests partners two biochemical markers, Tau and beta-amyloid (A beta 42) to determine their levels in cerebrospinal fluid. Results can determine Alzheimer's with 95% accuracy in 60% of patients over 60 showing signs of dementia.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.